Grainne O'Kane· @graokane · X·· 2 天前评分90
正文 · 机器翻译
AMPLIFY-7P 随机 ph2
✅7价（camupepimut）mKRAS 淋巴结靶向两亲性分子
➡️以治愈为目标 & <6mth 无复发 #PDAC
✅T 细胞应答，主要终点阴性
➡️在 ctDNA 阴性且未接受放疗者中获益？
➡️6个月时 DFS 获益 14%，p=0.056
✅计划开展 ph3
@myESMO @OncoAlert #ESMO26
452 浏览 · 9 赞 · 13 转发 · 1 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.orgLBA83按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study
https://esmocongress.esmo.org帖内回复
- Santhosh Ambika@RenoHemonc
@graokane @myESMO @OncoAlert Neoantigen based probably better than off the shelf ?
来源：Grainne O'Kane · x.com